9分钟双能峰时缩短360° CZT全身[177Lu]Lu-PSMA SPECT/CT与[68Ga]Ga-PSMA PET的对比评估
研究在20例前列腺癌患者中,将首次[177Lu]Lu-PSMA治疗后的360° CZT全身SPECT列表模式数据重建为单能18分钟(SP-18)、双能9分钟(DP-9)和双能18分钟(DP-18),并对比肿瘤体积与SUVmean,同时以治疗前[68Ga]Ga-PSMA PET为外部参考。结果显示DP-9的肿瘤体积和SUVmean与DP-18相当;与SP-18相比DP-9肿瘤体积更低而SUVmean相似;与PET相比SPECT的SUVmean和肿瘤体积均更高。结论认为双能9分钟采集可提供与已验证18分钟单能方案相当的肿瘤体积和SUVmean测量。
要点
- 双能9分钟全身[177Lu]Lu-PSMA SPECT/CT的肿瘤体积和SUVmean与双能18分钟重建相当。
- 与单能18分钟相比,双能9分钟肿瘤体积中位低15%,SUVmean相似。
- 与[68Ga]Ga-PSMA PET相比,SPECT的SUVmean和肿瘤体积均更高。
核心结论
- 双能360° CZT全身[177Lu]Lu-PSMA SPECT/CT可实现9分钟采集,其肿瘤体积和SUVmean与先前验证的18分钟单能方案相当。
- 双能9分钟方案的肿瘤体积低于单能18分钟方案,但更接近PET衍生值。
- SPECT与PET之间SUVmean差异主要反映注射至显像时间不同,肿瘤体积差异主要反映空间分辨率不同。
研究设计与样本
- 在20例前列腺癌患者中,于首次[177Lu]Lu-PSMA治疗注射后行360° CZT全身177Lu标记SPECT采集,自同一列表模式数据集重建SP-18、DP-9和DP-18并比较肿瘤体积与SUVmean。
- 以标准治疗前[68Ga]Ga-PSMA PET作为外部显像参考。
- 体模结果在各SPECT重建间相似,PET在SUV和体积的恢复系数上更优。
主要发现
- DP-9的肿瘤体积和SUVmean与DP-18相当。
- 与SP-18相比,DP-9肿瘤体积更低,中位百分比差异为-15%(四分位距-25%至-12%),SUVmean相似。
- 与PET相比,SP-18和DP-9的SUVmean分别高+14%(+7%至+36%)和+19%(-3%至+38%)。
- 与PET相比,SP-18和DP-9的肿瘤体积分别高+68%(+5%至+122%)和+47%(-15%至+95%)。
关键数值与推荐
- 双能113-keV和208-keV采集使获得计数增加逾2倍,允许采集时间缩短至9分钟(DP-9)。
- 单能113-keV 177Lu光电峰18分钟采集(SP-18)先前已被报道适用于[177Lu]Lu-PSMA治疗监测。
临床怎么用
- 在[177Lu]Lu-PSMA治疗监测中,可采用双能360° CZT全身SPECT/CT的9分钟采集方案替代18分钟单能方案,以获得相当的肿瘤体积和SUVmean测量。
- 解读SPECT与PET的SUVmean和肿瘤体积差异时,需考虑注射至显像时间及空间分辨率的影响。
局限性
- 样本量为20例前列腺癌患者。
- 体模中PET在SUV和体积的恢复系数上优于SPECT重建。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Eighteen-minute 360° cadmium zinc telluride (CZT) total-body 177Lu-labeled SPECT acquisitions on the single 113-keV 177Lu photopeak (SP-18) have been reported to be suitable for monitoring [177Lu]Lu-PSMA therapy. This study evaluated dual-energy 113- and 208-keV acquisitions with a more than 2-fold increase in acquired counts, allowing acquisition time to be reduced to 9 min (DP-9). Methods: In 20 patients with prostate cancer, 360° CZT total-body 177Lu-labeled SPECT acquisitions performed after the first [177Lu]Lu-PSMA therapeutic injection were reconstructed as SP-18, DP-9, and dual-energy 18-min reconstructions (DP-18), all from the same list-mode dataset, and tumor volume and SUVmean were compared. A standard pretherapy [68Ga]Ga-PSMA PET was also used as an external imaging reference. Results: DP-9 yielded tumor volume and SUVmean that were comparable to those of DP-18. Compared with SP-18, DP-9 produced lower tumor volumes (median percentage difference, -15% [interquartile range, -25% to -12%]) with similar SUVmean Compared with PET, both SP-18 and DP-9 showed higher SUVmean (+14% [+7% to + 36%] and +19% [-3% to +38%], respectively), likely reflecting the longer injection-to-imaging delay for SPECT, and higher tumor volumes (+68% [+5% to + 122%] and +47% [-15% to +95%], respectively), consistent with the lower spatial resolution of SPECT. Phantom results were similar for SPECT reconstructions, with PET showing better recovery coefficients for SUV and volume. Conclusion: Dual-energy 360° CZT total-body [177Lu]Lu-PSMA SPECT/CT enables 9-min acquisitions while providing tumor volume and SUVmean measurements comparable to those of the previously validated 18-min single-energy protocol. Tumor volumes are lower than those with SP-18 but are closer to PET-derived values. Differences between SPECT and PET mainly reflect the injection-to-imaging time for SUVmean and the spatial resolution for tumor volume.
引用
- Boursier C, Heyer S, Zouaoui A, et al. Evaluation of 9-Minute Dual-Energy Peak Time-Reduced 360° CZT Total-Body [177Lu]Lu-PSMA SPECT/CT Imaging with Comparisons to [68Ga]Ga-PSMA PET. J Nucl Med. 2026. PMID: 42492998. doi:10.2967/jnumed.126.272647
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。